We Think Green Cross Health's (NZSE:GXH) Statutory Profit Might Understate Its Earnings Potential

As a general rule, we think profitable companies are less risky than companies that lose money. Having said that, sometimes statutory profit levels are not a good guide to ongoing profitability, because some short term one-off factor has impacted profit levels. This article will consider whether Green Cross Health's (NZSE:GXH) statutory profits are a good guide to its underlying earnings.

We like the fact that Green Cross Health made a profit of NZ$15.3m on its revenue of NZ$570.3m, in the last year. While it managed to grow its revenue over the last three years, its profit has moved in the other direction, as you can see in the chart below.

See our latest analysis for Green Cross Health

earnings-and-revenue-history
NZSE:GXH Earnings and Revenue History November 29th 2020

Of course, when it comes to statutory profit, the devil is often in the detail, and we can get a better sense for a company by diving deeper into the financial statements. As a result, today we're going to take a closer look at Green Cross Health's cashflow, and unusual items, with a view to understanding what these might tell us about its statutory profit. Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Green Cross Health.

Advertisement

A Closer Look At Green Cross Health's Earnings

Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. This ratio tells us how much of a company's profit is not backed by free cashflow.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

For the year to September 2020, Green Cross Health had an accrual ratio of -0.34. That implies it has very good cash conversion, and that its earnings in the last year actually significantly understate its free cash flow. In fact, it had free cash flow of NZ$67m in the last year, which was a lot more than its statutory profit of NZ$15.3m. Green Cross Health shareholders are no doubt pleased that free cash flow improved over the last twelve months. Having said that, there is more to the story. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part.

How Do Unusual Items Influence Profit?

Green Cross Health's profit was reduced by unusual items worth NZ$4.7m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. In a scenario where those unusual items included non-cash charges, we'd expect to see a strong accrual ratio, which is exactly what has happened in this case. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Green Cross Health doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

Our Take On Green Cross Health's Profit Performance

In conclusion, both Green Cross Health's accrual ratio and its unusual items suggest that its statutory earnings are probably reasonably conservative. After considering all this, we reckon Green Cross Health's statutory profit probably understates its earnings potential! In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Green Cross Health and you'll want to know about it.

After our examination into the nature of Green Cross Health's profit, we've come away optimistic for the company. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

When trading Green Cross Health or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

About NZSE:GXH

Green Cross Health

Provides health care and advice services to communities in New Zealand.

Good value with proven track record.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0776.1% undervalued
210 users have followed this narrative
1 users have commented on this narrative
30 users have liked this narrative
SI
SimpleMan887
GME logo
SimpleMan887 on GameStop ·

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves

Fair Value:US$22089.6% undervalued
53 users have followed this narrative
2 users have commented on this narrative
21 users have liked this narrative
YI
HSAI logo
yiannisz on Hesai Group ·

The First Real Lidar Winner

Fair Value:US$27.0719.6% undervalued
13 users have followed this narrative
1 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
TSM logo
tripledub on Taiwan Semiconductor Manufacturing ·

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth

Fair Value:US$3814.1% undervalued
10 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

GO
NLBR logo
GoranLagea on Nova Ljubljanska Banka d.d ·

Nova Ljubljanska Banka d.d. future looks bright with a profit margin change of 38%

Fair Value:€36039.2% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FA
FIBRO logo
FA_Trader on Fibromat (M) Berhad ·

Fibromat: More than just a niche player, with clearer earnings visibility from order book and project wins

Fair Value:RM 1.0519.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
3696 logo
AstrisCorporateAdvisory on Ceres ·

Proven business incubator in transition

Fair Value:JP¥2.37k36.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3955.6% undervalued
43 users have followed this narrative
3 users have commented on this narrative
41 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.1k% overvalued
36 users have followed this narrative
11 users have commented on this narrative
31 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3136.5% undervalued
1348 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative